"Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR."
"Alnylam Pharmaceuticals represents the most transformative platform play on this list. FY2025 revenue surged 65.2% YoY to $3.71 billion, with AMVUTTRA generating $826.6 million in Q4 2025 (+189% YoY) following its landmark ATTR-CM approval. The company achieved full-year GAAP profitability for the first time in 2025 with net income of $313.7 million."
Oncology mergers and acquisitions are increasing as large pharmaceutical companies aim to replenish their pipelines amid patent expirations. Five biotechs are highlighted as attractive acquisition targets due to their unique mechanisms, commercial success, or innovative technologies. Incyte leads with significant revenue and a robust pipeline, while Alnylam Pharmaceuticals showcases a transformative RNAi platform. Both companies demonstrate strong financial performance and growth potential, making them appealing to potential acquirers looking for immediate revenue and strategic advantages.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]